Patents
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
04/2002
04/23/2002US6376653 Tie2 antagonist antibodies
04/23/2002US6376651 Amino acid sequences of a caf 1-related protein and to the use of these sequences in the diagnosis, treatment, and prevention of disorders associated with cell proliferation and inflammation.
04/23/2002US6376548 Enhanced propertied pesticides
04/23/2002US6376540 Furan nitrone compounds
04/23/2002US6376538 Antiinflammatory agents; autoimmune diseases
04/23/2002US6376519 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2
04/23/2002US6376517 For treating vision loss, preventing vision degeneration, and promoting vision regeneration (?neopsis?)
04/23/2002US6376498 Pharmaceutical, cosmetic and/or food composition with antioxidant properties
04/23/2002US6376493 Selective inhibition of phosphodiesterase iv and tumor necrosis factor; useful in treating osteoporosis, tumors, autoimmune diseases, rheumatic diseases, and asthma
04/23/2002US6376489 Cyclic AMP-specific phosphodiesterase inhibitors
04/23/2002US6376480 Vitamin D derivatives with substituents at C-25, process for their production, intermediate products and use for the production of pharmaceutical agents
04/23/2002US6376214 DNA encoding a novel homolog of CSBP/p38 MAP kinase
04/23/2002US6375975 Pharmaceutical compositions for buccal and pulmonary application
04/23/2002US6375972 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
04/23/2002US6375929 Gene therapy for inhibition of angiogenesis
04/23/2002CA2004127C Novel aminobenzoates
04/18/2002WO2002031511A2 Modulation of ligand binding/enzymatic activity of alpha beta proteins
04/18/2002WO2002031142A2 Antisense nucleic acid against alphav integrin
04/18/2002WO2002031115A2 Nucleic acid molecules and polypeptides for immune modulation
04/18/2002WO2002030983A2 Plasma fraction containing bikunin, method for the production thereof and use of the same
04/18/2002WO2002030956A1 N-alkylglycine trimeres capable of blocking the response to chemical substances, heat stimuli or mediators of neuronal receptor inflammation and compositions containing said trimeres
04/18/2002WO2002030938A1 Benzhydryl derivatives
04/18/2002WO2002030937A2 Labeled resiniferatoxin derivatives for use in vanilloid receptor binding assay
04/18/2002WO2002030936A1 Pyrrole-condensed morphinoid derivatives
04/18/2002WO2002030935A1 Morphinoid derivatives as delta-opioid agonists and antagonists
04/18/2002WO2002030933A1 Substituted 3.4-dihydro-pyrido[1,2-a]pyrimidines
04/18/2002WO2002030924A1 Quinazoline derivatives with anti-tumour activity
04/18/2002WO2002030911A1 Pyrimidinone derivatives and their use in the treatment of atherosclerosis
04/18/2002WO2002030910A1 (2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use
04/18/2002WO2002030908A1 Inhibitors of protein kinases
04/18/2002WO2002030907A1 Pyrazole derivatives for the treatment of viral diseases
04/18/2002WO2002030904A1 Pyridinone derivatives for treatment of atherosclerosis
04/18/2002WO2002030899A1 N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr3 receptor antagonists
04/18/2002WO2002030898A1 N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists
04/18/2002WO2002030895A1 SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS
04/18/2002WO2002030892A1 Butenolide and pentenolide derivatives as kinase inhibitors
04/18/2002WO2002030888A2 Tricyclic compounds and uses thereof
04/18/2002WO2002030884A2 Sulfide and disulfide compounds and compositions for cholesterol management and related uses
04/18/2002WO2002030882A2 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
04/18/2002WO2002030881A1 Sulfonylguanidine
04/18/2002WO2002030875A1 Beta-amino acid derivatives as integrin receptor antagonists
04/18/2002WO2002030870A2 Substituted c-cyclohexylmethylamine derivatives
04/18/2002WO2002030866A1 Nitroderivatives as drugs for diseases having an inflammatory basis
04/18/2002WO2002030863A2 Ether compounds and compositions for cholesterol management and related uses
04/18/2002WO2002030860A2 Ketone compounds and compositions for cholesterol management and related uses
04/18/2002WO2002030473A1 Targeted therapeutic agents
04/18/2002WO2002030428A1 Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting medicaments
04/18/2002WO2002030423A1 NF-λB INHIBITORS
04/18/2002WO2002030409A2 Methods for the treatment of a traumatic central nervous system injury
04/18/2002WO2002030407A1 ESTROGEN RECEPTOR-β LIGANDS
04/18/2002WO2002030396A1 Medication delivery devices
04/18/2002WO2002030385A2 Anti-inflammatory active ingredients
04/18/2002WO2002030353A2 NF-λB INHIBITORS
04/18/2002WO2002017914A3 Fused pyrrolocarbazoles against inflammation
04/18/2002WO2002014499A9 Claudin polypeptides
04/18/2002WO2002012210A9 Biphenyl derivatives and their use as ppar-gamma receptor activators
04/18/2002WO2002008272A3 High affinity soluble interleukin-18 receptor
04/18/2002WO2002008217A3 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
04/18/2002WO2002008177A8 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives
04/18/2002WO2002007721A3 Use of cox-2 inhibitors for preventing immunodeficiency
04/18/2002WO2002006478A3 Extracellular matrix protein
04/18/2002WO2002002541A3 Inhibitors of copper-containing amine oxidases
04/18/2002WO2001085715A3 Aza- and polyazanthranyl amides and their use as medicaments
04/18/2002WO2001082958A3 Methods of producing membrane vesicles
04/18/2002WO2001082952A3 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
04/18/2002WO2001081574A3 Regulation of nf-at interacting protein nip 45 variant
04/18/2002WO2001072777A3 Human transcription factors
04/18/2002WO2001068570A3 Il-8 receptor antagonists
04/18/2002WO2001068569A3 Il-8 receptor antagonists
04/18/2002WO2001068070A3 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
04/18/2002WO2001058916A3 Antibodies to ccr5
04/18/2002WO2001058893A3 Indol-3-yl derivatives and their use as integrin inhibitors
04/18/2002WO2001053330A3 High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them
04/18/2002WO2001026656A3 5-membered heterocycle derivatives and use thereof as monoamine oxidase inhibitors
04/18/2002WO2001025437A3 Growth factor polypeptides and nucleic acids encoding same
04/18/2002WO2000070341A9 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer
04/18/2002WO2000066106A9 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
04/18/2002US20020045765 Tocopherol derivatives and method for preparation thereof
04/18/2002US20020045652 Prophylactic or therapeutic drug for renal diseases
04/18/2002US20020045644 2-phenylpyran-4-one derivatives
04/18/2002US20020045642 Antiinflammatory, -arthritic and -emetic agents; central nervous system disorders; Parkinson's disease; antidepressants; psychological disorders; anxiolytic agents; antagonists of substance P receptors
04/18/2002US20020045623 Stable; potent; penetrates cell membranes; effectively hinders cellular apoptosis; Antiinflammatory agents, Ischemic agents, cancer, autoimmune diseases and nervous system disorders.
04/18/2002US20020045613 1-aroyl-piperidinyl benzamidines
04/18/2002US20020045601 Ophthalmic compositions
04/18/2002US20020045575 Treating inflammatory, autoimmune diseases, including graft-versus-host disease and enhancement of graft/tissue survival following transplant
04/18/2002US20020045568 Use of mp52 0r mp121 for treating and preventing diseases of the nervous system
04/18/2002US20020045222 Compositions and methods for saccharide synthesis
04/18/2002US20020045213 IL-17 receptor like molecules and uses thereof
04/18/2002US20020045203 Method for detecting active ingredients of medical value
04/18/2002US20020044972 Nucleic acid or oligonucleotide and a positively charged, aminated ethylene oxide-propylene oxide block copolymer
04/18/2002US20020044936 Administering a monoclonal antibody or fragment thereof which acts as an antagonist of the integrins GPIIb/IIIa ( alpha IIb beta 3) and alpha v beta 3; also treating inflammatory diseases such as rheumatoid arthritis, psoriasis
04/18/2002US20020044921 Pegylated interleukin-10
04/18/2002DE10050663A1 Use of amino-substituted imidazo(1,2-a)pyridine, imidazo(1,2-a)pyrimidine and imidazo(1,2-a)pyrazine derivatives as NO synthase inhibitors, e.g. in treatment of migraine and neurodegenerative diseases
04/18/2002DE10050662A1 New substituted dihydropyrido-pyrimidine derivatives, useful for treating e.g. pain, urinary incontinence and tinnitus
04/18/2002DE10050661A1 New substituted 3,4-dihydro-pyrimido(1,2-a)pyrimidine and 3,4-dihydro-pyrazino(1,2-a)pyrimidine derivatives useful for the treatment of pain, urinary incontinence, pruritis, tinnitus and diarrhea
04/18/2002DE10047319A1 Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können Use of R-arylpropionic acids for producing medicaments for treating diseases that can be therapeutically affected by the inhibition of activation of the nuclear transcription factor AP-1
04/18/2002CA2459746A1 Pyrimidinone derivatives and their use in the treatment of atherosclerosis
04/18/2002CA2427499A1 Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-.gamma. binding agents
04/18/2002CA2425678A1 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
04/18/2002CA2425674A1 Sulfide and disulfide compounds and compositions for cholesterol management and related uses